Navigation Links
Heska Announces Launch of New Website
Date:11/19/2009

LOVELAND, Colo., Nov. 19 /PRNewswire-FirstCall/ -- In a series of new initiatives to enhance its customers' experience, Heska Corporation (Nasdaq: HSKA) ("Heska" or the "Company") announced today the launch of its new and improved website. The upgraded site is the result of several months of analysis, design and programming to align the site with the company's new brand image and strategic objectives.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)

In addition to the site's many new technical features, the design and interface present a dramatic improvement. The site's navigation is streamlined, making it more intuitive and user-friendly. In the coming weeks, Heska will be introducing new site features including a login where pages are populated with user defined content, special offers and access for continuing education opportunities. Of special interest is an exciting new online customer rewards program that will be launching, unique to Heska, and designed specifically to benefit our veterinary partners.

"We think this presentation provides greater ease and efficiency as users access their resources while simultaneously inviting the veterinary industry to learn more about Heska's stream of new solutions for their practice. This new site coming online is part of a larger effort to offer our customers the best possible service and support," said Michael J. McGinley, President and Chief Operating Officer of Heska Corporation.

Heska's website can be viewed at www.heska.com.

About Heska

Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future operations. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that these statements are based on current plans, which may not be fulfilled as expected and may not have the positive impact even if fulfilled as expected. In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to the loss of access to products from Abbott Point of Care Inc. after November 1, 2009, which represent approximately 18% of Heska's revenue for the year ended September 30, 2009; uncertainties regarding Heska's reliance on third parties to whom Heska has granted substantial marketing rights to certain of Heska's existing products and whom may be large Heska customers; uncertainties regarding Heska's ability to generate profits and positive cash flow in future periods; uncertainties surrounding the success of future products, including Heska's ability to adhere to stated deadlines and successfully commercialize such products; risks regarding Heska's ability to successfully market, sell and distribute its products in an economically sustainable manner; uncertainties related to Heska's ability to maintain its listing on the Nasdaq Capital Market; competition, including uncertainties regarding the impact of new products competitors have recently launched or may launch in the future; risks regarding Heska's reliance on third-party suppliers, which is substantial and could have significant negative consequences if Heska were to lose exclusive rights or access to a product due to a supplier decision or for other reasons; risks related to Heska's reliance on third parties to properly and timely complete certain research and development activities; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 2008 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2009.

SOURCE Heska Corporation


'/>"/>
SOURCE Heska Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Heska Announces Q309 Results
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., ... , today announced that the company has provided ... University of North Carolina at Chapel Hill and to ... designed to characterize and quantify HIV reservoir and viral ... pharmacological intervention. The HIV Cure Center is a joint ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology:
(Date:8/18/2017)... St. Louis, Missouri (PRWEB) , ... August 18, 2017 , ... ... ” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To ... way they help children learn social and emotional skills, she created the Time-In Toolkit, ...
(Date:8/18/2017)... ... August 18, 2017 , ... With ... specializing in bioidentical hormone replacement therapy and integrative medicine, has become a frontrunner ... of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. , ...
(Date:8/18/2017)... ... 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... on false teachings pertaining to the mother of the Savior whom the world calls “Mother ... different picture of the role of this historical woman. , “The world bows, kisses ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that ... its marketing efforts with its product now available through Jet.com. , After 25 ... The effervescent powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced ...
(Date:8/18/2017)... CA & CARMEL, IN (PRWEB) , ... August 18, 2017 , ... ... on its 36th annual list, the most prestigious ranking of the nation's fastest-growing private ... been included in the exclusive Inc. 5000 ranking . This year’s ranking reflects ...
Breaking Medicine News(10 mins):